CORDIS
EU research results

CORDIS

English EN
CONtrol of COmmunity-acquired MRSA: Rationale and Development of counteractions

CONtrol of COmmunity-acquired MRSA: Rationale and Development of counteractions

Objective

Until recently, methicillin-resistant Staphylococcus aureus (MRSA) were confined to hospitals (HA-MRSA). However, community- and farm-associated MRSA (CA-and FA-MRSA) has developed as an important cause of infections. No strategies exist to combat these MRSA. CONCORD is aimed at explaining the ecological success in the community and the farm environment of CA- and FA-MRSA in contrast to HA-MRSA in order to facilitate the rationale and development of effective strategies against CA- and FA-MRSA. Epidemiology of CA-MRSA is complex and incomplete. To obtain both a more complete description of the epidemiology of CA-MRSA and recent isolates small scale surveillance will be performed among patients in the 20 most populous EU countries, pig farms in major pig exporting countries and important veal calve raising countries. Genomics data for CA-MRSA are limited and non-existent for FA-MRSA. Successful adaptation of MRSA to a new environment supposes either the acquisition of novel properties or the differential expression of genes already present. Only 2 CA-MRSA have been fully sequenced and the UMCU has sequenced a FA-MRSA. Whole genome sequencing, comparative genome hybridization and transcriptomics will be used to understand the genetic adaptations of MRSA in the community. The contribution of putative virulence factors to pathogenicity will be studied by knock-outs and complemented strains of these knock-outs. The strains will be tested in in vitro and ex vivo models to establish their physiological role. Mathematical modelling is an important tool to manage infection control. A few models exist that evaluate measures to reduce transmission of HA-MRSA or CA-MRSA in jails. No models are available for FA-MRSA. Modelling will provide both fundamental insights on MRSA epidemiology as well as specific recommendations or testable hypotheses for human and veterinary clinical practice. The potential of intervention strategies to combat CA- and FA-MRSA will be determined.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Address

Heidelberglaan 100
3584 Cx Utrecht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 679 471

Administrative Contact

Susan Zwaagstra (Dr.)

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITE LYON 1 CLAUDE BERNARD

France

EU Contribution

€ 226 800

INSTITUTO DE TECNOLOGIA QUIMICA E BIOLOGICA - UNIVERSIDADE NOVA DE LISBOA

Portugal

EU Contribution

€ 202 512

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 225 000

THE UNIVERSITY OF EDINBURGH

United Kingdom

EU Contribution

€ 311 308

National Medicines Institute (Narodowy Instytut Lekow)

Poland

EU Contribution

€ 235 200

DANMARKS TEKNISKE UNIVERSITET

Denmark

EU Contribution

€ 353 092

UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 525 257

NOVOLYTICS LIMITED

United Kingdom

EU Contribution

€ 235 552

Project information

Grant agreement ID: 222718

Status

Closed project

  • Start date

    1 January 2009

  • End date

    30 June 2012

Funded under:

FP7-HEALTH

  • Overall budget:

    € 3 937 759,60

  • EU contribution

    € 2 994 192

Coordinated by:

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands